Abbott Laboratories Aktie
| 115,92USD | -1,21USD | -1,03% |
WKN: 850103 / ISIN: US0028241000
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 99,34 |
| Vanguard Group, Inc. (Subfiler) | 9,21 |
| The Vanguard Group, Inc. | 8,99 |
| State Street Corp. | 4,41 |
| Capital Research & Management Co. (International Investors) | 3,78 |
| Vanguard Total Stock Market ETF | 3,17 |
| Capital Research & Management Co. (Global Investors) | 3,06 |
| BlackRock Fund Advisors | 2,82 |
| Vanguard 500 Index Fund | 2,62 |
| BlackRock Institutional Trust Co. NA | 2,14 |
| Geode Capital Management LLC | 2,01 |
| Wellington Management Co. LLP (Wellington Breakout) | 1,44 |
| Fidelity 500 Index Fund | 1,23 |
| SPDR S&P 500 ETF Trust | 1,21 |
| Norges Bank (13F) | 1,17 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 107 000 | 109 000 | 113 000 | 115 000 | 114 000 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,30 | 0,32 | 0,38 | 0,38 | 0,35 |
Bilanz (in Mio. USD) - Aktiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 15 667 | 20 441 | 24 239 | 25 224 | 22 670 |
| Summe Anlagevermögen | 52 220 | 52 107 | 50 957 | 49 214 | 50 544 |
| Summe Aktiva | 67 887 | 72 548 | 75 196 | 74 438 | 73 214 |
Bilanz (in Mio. USD) - Passiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 19 099 | 19 890 | 19 251 | 17 946 | 15 873 |
| Summe Fremdkapital | 36 586 | 39 545 | 39 172 | 37 533 | 34 387 |
| Summe Eigenkapital | 31 301 | 33 003 | 36 024 | 36 905 | 38 827 |
| Summe Passiva | 67 887 | 72 548 | 75 196 | 74 438 | 73 214 |
Adresse
| 100 Abbott Park Road, 60064-6400 Abbott Park | |
| Telefon | +1 (224) 667-6100 |
| Internet | http://www.abbott.com |
Management
|
Alison Davies
Treasurer & Vice President |
|
Andrea F. Wainer
Executive VP-Rapid & Molecular Diagnostics |
|
Claire L. Babineaux-Fontenot
Independent Director |
|
Daniel Gesua Sive Salvadori
Executive Vice President-Nutritional Products |
|
Daniel J. Starks
Independent Director |
|
Darren W. McDew
Independent Director |
|
Gene Huang
Chief Economist & Vice President |
|
Hubert L. Allen
Secretary, Executive VP & General Counsel |
|
Jim Leffelman
Manager-Expense Reporting |
|
Joanne T. Beck
Global Pharmaceutical Operations |
|
John A. McCoy
Vice President-Finance & Controller |
|
John G. Stratton
Independent Director |
|
John M. Capek
Executive Vice President-Ventures |
|
Karen Wong Chayavirabood
Regional Director-Asia |
|
Kathryn S. Collins
Vice President-Commercial Legal Operations |
|
Lisa D. Earnhardt
Group President-Medical Devices & Executive VP |
|
Mary K. Moreland
Executive Vice President-Human Resources |
|
Melissa Brotz
Chief Marketing & Communications Officer |
|
Michael F. Roman
Independent Director |
|
Michael G. O'Grady
Independent Director |
|
Michelle A. Kumbier
Independent Director |
|
Nancy McKinstry
Independent Director |
|
Paola Gonzalez
Independent Director |
|
Philip P. Boudreau
Chief Financial Officer & Senior VP-Finance |
|
Randel William Woodgrift
Senior Vice President-Cardiac Rhythm Management |
|
Robert B. Ford
Chairman, President & Chief Executive Officer |
|
Robert J. Alpern
Independent Director |
|
Sally E. Blount
Independent Director |
|
Scott J. House
Senior VP-Regulatory & Engineering Services |
|
Scott Leinenweber
Senior Vice President-Licensing & Acquisitions |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
